CRSP
CRISPR Therapeutics AG
Stock
$55.43−0.01 (−0.02%)Close Oct 2, 2026
Balance sheet
| Line | Q2 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $2.4B | $2.0B | $1.9B | $1.7B | $1.8B | $2.4B | $1.7B | $944M | $457M | $240M | $316M | $156M | $945K |
| Current assets | $2.4B | $2.0B | $1.9B | $1.9B | $1.9B | $2.4B | $1.7B | $988M | $466M | $248M | $320M | $157M | — |
| Intangible assets | — | — | $0 | $16K | $71K | $125K | $180K | $235K | $289K | $344K | $399K | $454K | — |
| Total assets | $2.7B | $2.3B | $2.2B | $2.2B | $2.2B | $2.8B | $1.8B | $1.1B | $489M | $271M | $345M | $159M | — |
| Current liabilities | $133M | $149M | $88M | $109M | $121M | $120M | $94M | $57M | $28M | $15M | $22M | $10M | — |
| Long-term debt | $586M | $0 | — | — | — | — | — | — | — | — | — | — | — |
| Total liabilities | $904M | $343M | $310M | $347M | $368M | $352M | $164M | $127M | $97M | $84M | $112M | $124M | — |
| Shareholders' equity | $1.7B | $1.9B | $1.9B | $1.9B | $1.9B | $2.4B | $1.7B | $939M | $392M | $188M | $233M | −$29M | −$7.0M |
| Shares outstanding | 96.7M | 96.0M | 85.8M | 80.3M | 78.6M | 77.1M | 75.4M | 60.8M | 52.3M | 47.0M | 39.8M | — | — |
| Current ratio | 17.85 | 13.32 | 22.07 | 17.54 | 15.30 | 20.17 | 18.21 | 17.29 | 16.81 | 17.12 | 14.56 | 15.44 | — |